Holen Sie sich die Stockscreener-App
0.2071
0.15%
0.0003
Handel nachbörslich:
.20
-0.0071
-3.43%
Schlusskurs vom Vortag:
$0.2068
Offen:
$0.185
24-Stunden-Volumen:
710.96K
Relative Volume:
1.12
Marktkapitalisierung:
$6.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.85M
KGV:
-0.0782
EPS:
-2.65
Netto-Cashflow:
$-46.25M
1W Leistung:
+8.43%
1M Leistung:
-24.85%
6M Leistung:
-65.54%
1J Leistung:
-68.04%
1-Tages-Spanne:
$0.185
$0.215
1-Wochen-Bereich:
$0.1831
$0.22
52-Wochen-Spanne:
$0.183
$9.3722
Vincerx Pharma Inc Stock (VINC) Company Profile
Firmenname
Vincerx Pharma Inc
Sektor
Branche
Telefon
650-800-6676
Adresse
260 SHERIDAN AVENUE, PALO ALTO
Vergleichen Sie VINC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.2071 | 6.97M | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-01-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-01 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-13 | Eingeleitet | Laidlaw | Buy |
| 2021-08-25 | Eingeleitet | B. Riley Securities | Buy |
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update - Defense World
Vincerx Pharma announces workforce reduction of 55%, cost-control measures - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.24 Amid Market Challenges - Investing.com UK
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Asianet Newsable
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of Vip943 - Marketscreener.com
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 - GlobeNewswire
Vincerx Pharma Reports Promising Cancer Drug Results, Explores Strategic Options Amid Cost Cuts - StockTitan
Vincerx Pharma gets extension to meet Nasdaq listing criteria - Investing.com
Vincerx Pharma gets extension to meet Nasdaq listing criteria By Investing.com - Investing.com UK
Leerink Partnrs Weighs in on Vincerx Pharma FY2024 Earnings - Defense World
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus.com
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - Quartz
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus.com
Vincerx Pharma Reports Q3 2024 Financial Results - TipRanks
Vincerx Pharma Inc reports results for the quarter ended September 30Earnings Summary - XM
Vincerx Pharma Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Reports Complete Responses in VIP943 Trial, Narrows Q3 Loss to $0.17/Share | VINC Stock News - StockTitan
VINC stock touches 52-week low at $0.32 amid market challenges - Investing.com Canada
SEC Form PRE 14A filed by Vincerx Pharma Inc. - Quantisnow
VINC Stock on the Rise: A Promising Investment - The InvestChronicle
Should investors be concerned about Vincerx Pharma Inc (VINC)? - US Post News
Financial Health Check: Examining Vincerx Pharma Inc (VINC)’s Key Ratios - The Dwinnex
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
Check Out Vincerx Pharma Inc (VINC)’s Trade Data Rather Than the Analysts’ Views - SETE News
Taking a Closer Look At Vincerx Pharma Inc (VINC) Following Its Recent Trade - Knox Daily
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges By Investing.com - Investing.com South Africa
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Wall Street Analyst Initiated Vincerx Pharma Inc [VINC]. What else is Wall St. saying - The DBT News
Vincerx stock tumbles 20% on corporate updates - MSN
Vincerx Pharma Inc (VINC) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Leerink Partners Cuts Vincerx Pharma (NASDAQ:VINC) Price Target to $2.00 - Defense World
Vincerx reports two complete responses in VIP943 study By Investing.com - Investing.com Australia
VINC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Vincerx stock tumbles 20% on corporate updates (NASDAQ:VINC) - Seeking Alpha
Leerink cuts Vincerx Pharma stock target on pipeline update By Investing.com - Investing.com UK
Financial Fitness Check: Examining Vincerx Pharma Inc (VINC)’s Key Ratios - The Dwinnex
Vincerx reports two complete responses in VIP943 study - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates - StockTitan
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? - MSN
Vincerx Pharma (NASDAQ:VINC) Trading Down 2.1% - Defense World
A better buy-in window may exist right now for Vincerx Pharma Inc (VINC) - SETE News
Investing in Vincerx Pharma Inc (VINC) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely - Simply Wall St
Companies Like Vincerx Pharma (NASDAQ:VINC) Could Be Quite Risky - Yahoo Finance
Vanguard Group Inc. Has $3.38 Million Position in Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Vincerx Pharma Announces Stock Option Repricing and Shareholder Approval - TipRanks
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024 - MSN
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Acadian Asset Management LLC Sells 36,571 Shares of Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Decreases By 31.7% - Defense World
Finanzdaten der Vincerx Pharma Inc-Aktie (VINC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):